News

How Glaucoma Device Companies Raise Funding to Navigate ‘Death Valley’

By Heather Johnson | March 6, 2019

SAN FRANCISCO – At the Glaucoma 360 New Horizons Forum here, Emmett Cunningham, Jr., MD, PhD, moderating a panel on financing for emerging glaucoma device…

10 Takeaways from Roche’s $4.8 Billion Offer to Acquire Spark Therapeutics

By Rich Kirkner | February 27, 2019

Here are 10 things to know about Roche’s $4.8 billion bid to acquire Spark Therapeutics. Roche’s $114.5-a-share offer is a 122% premium over the closing…

Corporate Leaders Explain the Upside of the Optometric Channel

By Karen Blum | February 27, 2019

NEW ORLEANS – Optometry has become a source of big business for ophthalmic companies over the past decade, with about 40 to 60% of sales…

Parsing the Challenges of Reimbursement in the Glaucoma Space: Drug and Device Developers Address Elephant in the Room

By Heather Johnson | February 20, 2019

SAN FRANCISCO – When it comes to securing reimbursement models, ophthalmic device and drug developers are facing mounting pressure. Payers are demanding more evidence on…

How Jim Thimons Helped Bring OIS’ Unique Approach to Talking About Innovation to Optometry and OIS@SECO 2019

By Rich Kirkner | February 14, 2019

When he attended his first Ophthalmology Innovation Summit at the American Society of Cataract and Refractive Surgery a few years ago, Jim Thimons, OD, recalls…

‘Shark Tank’-like Winning Pitch Challenge Beckons Innovative Ideas by February 18

By Steve Lenier | February 14, 2019

A new Winning Pitch Challenge (WPC) symposium is coming to the 2019 American Society of Cataract and Refractive Surgery meeting, providing an opportunity for entrepreneurs…

The State of the Art of Glaucoma Genetics

By Heather Johnson | February 5, 2019

SAN FRANCISCO – Advances in glaucoma genetics potentially hold the key to new therapies for prevention, early detection, and a cure, researcher Janey L. Wiggs,…

How Green Surgery Practices Are Reducing Greenhouse Gasses and Waste, and Cutting Costs

By Michelle Dalton | January 30, 2019

Surgery in most high-income countries generates large quantities of waste. For instance, single-use disposable instruments are often used in a variety of surgery settings, but…

Nicox Patiently Pursues Moves to Build Value

By Steve Lenier | January 23, 2019

Nicox SA has taken several steps in the past few months to increase shareholder value. It has two product candidates headed toward Phase II trials,…

After XLRS Gene Therapy Disappoints, AGTC Looks to ‘Transformative Year’

By Rich Kirkner | January 16, 2019

Since announcing disappointing clinical trial results for one of its lead ophthalmic gene therapy candidates and the termination of its collaboration agreement with Biogen, Applied…

OIS Index Follows the Stock Market Lower in December

By Michael Lachman | January 10, 2019

The OIS Index declined 11% in December, marking the fourth month in a row in which ophthalmic stocks lost value. For the month, the overall…

Will Changes in the FDA’s 510(k) Process Be Good for Innovators?

By Steve Lenier | January 1, 2019

Key players in the medical device industry, including one major player in ophthalmology, have issued mixed reviews in response to the Food and Drug Administration’s…

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.